MGEN - シグナル・ジェネティクス (Miragen Therapeutics Inc.) シグナル・ジェネティクス

 MGENのチャート


 MGENの企業情報

symbol MGEN
会社名 Miragen Therapeutics Inc (シグナル・ジェネティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical Specialities  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ミラジェン・セラピューティクス(Miragen Therapeutics Inc.)(旧名: Signal Genetics Inc.)は臨床病期のバイオ医薬品会社である。同社はマイクロRNAに焦点を置いて、満たされていない医療ニーズが高い病気に役立つリボ核酸(RNA)標的治療薬の発見・開発に従事する。特定の癌治療用臨床製品候補MRG-106は、いくつかの血液癌で異常に高レベルに見られるマイクロRNA-155(miR-155)の阻害剤である。病理学的線維症の治療用臨床製品候補MRG-201は、心臓、腎臓、肝臓、肺線維症及び全身性硬化症を含む多様な病理学的線維症状態において異常に低いレベルで見出されるmiR-29の代替物である。臨床プログラムに加えて、前臨床製品候補のパイプラインの発見・開発を行う。同社の前臨床製品候補はMRG-107とMRG-110を含む。  シグナル・ジェネティクスは米国のバイオテクノロジ―メ―カ―。がん患者のケアおよび治療に焦点を充てた診断製品の開発とサ―ビスに注力する。主な製品には多発性骨髄腫のリスクが高い患者を特定する遺伝子シグネチャ―検査「MyPRS (Myeloma Prognostic Risk Signature)」がある。   Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.
本社所在地 6200 Lookout Road Boulder CO 80301 USA
代表者氏名 William Stuart Marshall ウィリアム・スチュアート・マーシャル
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 303-531-5952
設立年月日 40179
市場名 NASDAQ Small Cap
ipoyear 2014年
従業員数 65人
url www.miragentherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/mgen
adr_tso
EBITDA EBITDA(百万ドル) -25.42500
終値(lastsale) 5.26
時価総額(marketcap) 159606073.6
時価総額 時価総額(百万ドル) 145.33670
売上高 売上高(百万ドル) 9.78900
企業価値(EV) 企業価値(EV)(百万ドル) 79.18570
当期純利益 当期純利益(百万ドル) -25.59500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Miragen Therapeutics Inc revenues increased from $1.2M to $7M. Net loss applicable to common stockholders decreased 6% to $13.4M. Revenues reflect Collaboration revenue increase from $498K to $6.1M Grant revenue increase of 23% to $842K. Lower net loss reflects General and administrative decrease of 14% to $4.5M (expense) Interest and other income increase from $132K to $528K (income).

 MGENのテクニカル分析


 MGENのニュース

   The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher  2019/11/13 12:10:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) Crispr Therapeutics AG (NASDAQ: CRSP ) Diplomat Pharmacy Inc (NYSE: DPLO )( warned of going concern risk) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) XOMA Corp (NASDAQ: XOMA ) Zai Lab Ltd (NASDAQ: ZLAB ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov.
   The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study  2019/10/29 11:32:34 Benzinga Feeds
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 28.) AstraZeneca plc (NYSE: AZN ) ( reported positive clinical readout for triple combo lung cancer drug) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Cabaletta Bio Inc (NASDAQ: CABA ) (went public Oct. 25) ESSA Pharma Inc (NASDAQ: EPIX ) IGM Biosciences Inc (NASDAQ: IGMS ) Novo Nordisk A/S (NYSE: NVO ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) (reacted to a positive clinical readout) Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 28.) Agile Therapeutics Inc (NASDAQ: AGRX ) (reported negative comments from FDA staff in the briefing document posted ahead of Twirla Adcom meeting) Bellerophon Therapeutics Inc (NASDAQ: BLPH ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Gritstone Oncology Inc (NASDAQ: GRTS ) Endologix, Inc. (NASDAQ: ELGX (FDA issued a safety communication to physicians and patients regarding Endologix AFX endovascular grafts) Hoth Therapeutics Inc (NASDAQ: HOTH ) KemPharm Inc (NASDAQ: KMPH ) Miragen Therapeutics Inc (NASDAQ: MGEN ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) Myovant Sciences Ltd (NYSE: MYOV ) Orgenesis Inc (NASDAQ: ORGS ) Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) Stocks In Focus Mirati's KRAS Inhibitor Shows Tumor Shrinkage Mirati Therapeutics Inc (NASDAQ: MRTX ) announced the first Phase 1/2 trial results for MRTX849, an investigational KRAS G12C inhibitor, in patients with solid tumors expressing KRAS G12C mutations.
   The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave  2019/09/27 11:56:12 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 26.) AstraZeneca plc (NYSE: AZN ) GlaxoSmithKline plc (NYSE: GSK ) Sanofi SA (NASDAQ: SNY ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Aduro BioTech Inc (NASDAQ: ADRO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) AnaptysBio Inc (NASDAQ: ANAB ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) AzurRx BioPharma Inc (NASDAQ: AZRX ) Bellerophon Therapeutics Inc (NASDAQ: BLPH ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (announced submission of clinical trial application to U.K. regulators for its investigational therapy for phenylketonuria) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) CytomX Therapeutics Inc (NASDAQ: CTMX ) strong>DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) ( announced mid-stage results of NASH treatment candidate) Enochian Biosciences Inc (NASDAQ: ENOB ) Erytech Pharma SA (NASDAQ: ERYP ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Gritstone Oncology Inc (NASDAQ: GRTS ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) IGM Biosciences Inc (NASDAQ: IGMS ) (initial public offering on Sept.
   Signal Genetics, Inc. (MGEN) Reports Q2 Loss, Tops Revenue Estimates  2019/08/08 00:45:06 Zacks Investment Research
Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of 21.62% and 184.07%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout  2019/08/07 11:34:05 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 6) Allakos Inc (NASDAQ: ALLK )(announced common stock offering) Cytokinetics, Inc. (NASDAQ: CYTK ) Insulet Corporation (NASDAQ: PODD )( reacted to forecast-beating second-quarter results) Fulgent Genetics Inc (NASDAQ: FLGT )(moved in reaction to second-quarter earnings) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 6) Abeona Therapeutics Inc (NASDAQ: ABEO ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM )(reacted to second-quarter results) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BIOLINERX LTD/S ADR (NASDAQ: BLRX )(reacted to second-quarter results) CELLECT BIOTECH/S ADR (NASDAQ: APOP ) ChemoCentryx Inc (NASDAQ: CCXI )(reported below-consensus second-quarter revenues) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Endo International PLC (NASDAQ: ENDP )(reacted to second-quarter results) Equillium Inc (NASDAQ: EQ ) Evogene Ltd (NASDAQ: EVGN ) Hepion Pharmaceuticals Inc (NASDAQ: HEPA ) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) MEI Pharma Inc (NASDAQ: MEIP ) Merit Medical Systems, Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 シグナル・ジェネティクス MGEN Miragen Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)